LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
BörsenkürzelLNSR
Name des UnternehmensLENSAR Inc
IPO-datumSep 21, 2020
CEOCurtis (Nicholas T)
Anzahl der mitarbeiter140
WertpapierartOrdinary Share
GeschäftsjahresendeSep 21
Addresse2800 Discovery Drive
StadtORLANDO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl32826
Telefon18885367271
Websitehttps://www.lensar.com/
BörsenkürzelLNSR
IPO-datumSep 21, 2020
CEOCurtis (Nicholas T)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten